Search
Kayleigh Keilty, Partner at Saul Ewing LLP, will be one of the speakers at this month's ACC NTIH. This program will provide an introduction to antitrust concepts, how they impact businesses, and best practices to ensure compliance. Attendees will receive an overview of the federal antitrust laws and...
Congratulations! After spending months preparing and submitting your marijuana license application, you have been selected by the Delaware Office of Marijuana Commissioner (OMC) to receive a coveted adult-use marijuana license — now the real work starts. Over the last eight years, I have helped...
Saul Ewing LLP is proud to announce that Charles M. Lizza, Vice Chair of the firm’s Litigation Department, was named to the NJBIZ 2024 Law Power 50 list. This is the sixth year in a row that Mr. Lizza has been included on this list of the state's top lawyers. Professionals are selected for the list...
An invention disclosure form is a document used to capture detailed information about a new invention or discovery. The first step in the patent application process, the form plays a crucial role in protecting intellectual property. A well-crafted invention disclosure form will create an accurate...
Introduction On June 18, 2024, the Federal Trade Commission (“FTC”) unanimously agreed to submit a comment supporting a recent proposed U.S. Patent and Trademark Office (“PTO”) rule that would mandate the disclosure of all settlement agreements made between parties appearing before the Patent Trial...
Delene Lantz, Counsel, Saul Ewing LLP, will speak at the PA Township Association of Supervisor’s (PSATS) Secretary and Township Managers Summit in Boalsburg, PA on Tuesday, June 18th. Her topic will be Managing Right-to-Know Requests. Get caught up on the latest news, RTKL decisions, and best...
On April 18, 2024, the Federal Trade Commission (FTC), U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services (HHS) collectively launched a new publicly accessible web portal to which members of the public can make reports of what they believe to be competition –...
With Kimble v. Marvel Entertainment, LLC , the U.S. Supreme Court upheld the controversial Brulotte v.Thys Co. decision, which prohibited collection of patent-based royalties that accrue after patent expiration. The Court expressly supported alternative licensing terms and business arrangements to...
In a conversational 30-minute forum over Zoom, Saul Ewing attorneys hosted a discussion on emerging industry developments and common issues that cannabis businesses face today. This month's program featured content covering current regulatory landscape and how it impacts your business. Interested in...
Intellectual Property 101 / Copyrights, Patents, and Trademarks…Oh My! Thomas Edison. Henry Ford. Steve Jobs. These three household names revolutionized modern society through the protections afforded to their intellectual property by U.S. patent laws. Traditionally a copyright attaches when the...
What's in a Name? The A to Z of Patent Inventorship Patent inventorship is a key element of protecting IP in both academia and industry and has given rise, in recent years, to high profile disputes and litigation. Proper inventorship determination is essential for researcher management, patent...
Saul Ewing attorneys hosted a timely discussion on topics relating to Minnesota’s new adult-use cannabis law. During this one-hour program, we examined the implications of the law for all Minnesota employers, including those relating to drug testing and drug-free workplace policies. We also...
January 26, 2024 - With AI poised to reshape the practice of law and businesses in every industry, Saul Ewing is pleased to partner with the ABA’s Intellectual Property Litigation Committee in forming the AI Subcommittee. The AI Subcommittee will monitor legal and technological developments in this...
On November 21, 2023, the Federal Trade Commission (FTC) approved a resolution allowing it to use “compulsory process in nonpublic investigations involving certain products and services that use or claim to be produced using artificial intelligence (AI) or claim to detect its use.” This allows the...
On May 18, 2023, the Supreme Court unanimously affirmed the Federal Circuit's decision, Amgen Inc. v. Sanofi, 987 F.3d 1080 (Fed. Cir. 2021), that the claims of two of Amgen's patents were invalid for lack enablement. The involved patents, US 8,829,165 and US 8,859,741, are directed to monoclonal...